RxDoctor Payments Data

Norma Schacherl, DO

Family Medicine · San Benito, TXNPI 1649277203

Payments from drug & device makers

$1,138in general payments, 2019–2025

Across 79 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$392
  • Novo Nordisk$163
  • Pfizer$87
  • Boehringer Ingelheim$86
  • Otsuka America Pharmaceutical, Inc.$42
  • Johnson & Johnson$38
  • plus $329 from 14 others

What the payments were for

  • Food & beverage$1,138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,138 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$50,913
Medicare patients
132
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$126,189
JardianceEmpagliflozin102$120,328
JanuviaSitagliptin Phosphate60$64,077
TrulicityDulaglutide35$62,979
FarxigaDapagliflozin Propanediol66$51,429
TradjentaLinagliptin47$40,135
MounjaroTirzepatide33$33,244
EliquisApixaban28$28,860
RybelsusSemaglutide17$27,750
XareltoRivaroxaban18$25,860
LinzessLinaclotide35$23,570
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$21,659
ShingrixVaricella-Zoster Ge/As01b/Pf95$19,853
JanumetSitagliptin Phos/Metformin Hcl20$18,712
Lagevrio (Eua)Molnupiravir23$18,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$86$167,722165 claims
Novo NordiskOzempic, Rybelsus$163$153,939139 claims
Lilly USA, LLCTrulicity, Mounjaro$392$96,22368 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta$33$57,507165 claims
AstraZenecaFarxiga$17$51,42966 claims
PfizerEliquis, Abrysvo$87$35,52350 claims
Johnson & JohnsonXarelto$38$25,86018 claims
AbbVieLinzess$27$23,57035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Benito

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →